Skip to main content

Table 6 Derived and existing utility decrements for minor and major bleeds ordered by magnitude

From: Health-related quality of life impact of minor and major bleeding events during dual antiplatelet therapy: a systematic literature review and patient preference elicitation study

Source

Utility decrement for minor bleeds

 EQ-5D-5 L UK tariff - PA

−0.000848

 EQ-5D-5 L to EQ-5D-3 L US value set - PA

−0.00137

 EQ-5D-5 L to EQ-5D-3 L UK value set - PA

−0.00140

 EQ-5D-3 L US tariff - PA

−0.00180

 Garg [28]

− 0.002

 EQ-5D-3 L UK tariff - PA

−0.00250

 Kazi [29]

−0.004

 EQ-5D-5 L UK tariff - SA

−0.00453

 EQ-5D-5 L to EQ-5D-3 L US value set - SA

−0.00566

 EQ-5D-3 L US tariff - SA

−0.00584

 EQ-5D-5 L to EQ-5D-3 L UK value set - SA

−0.00661

 EQ-5D-3 L UK tariff - SA

−0.00828

 Liew [30]

− 0.02

 Amin [11]

−0.0257 (BARC type 1)

Source

Utility decrement for major bleeds

 Schleinitz [32]

−0.005 (GI bleeding)

 Greenhalgh [27]

− 0.007

 Kazi [29]

−0.01 (CABG-related)

 Gupta [31]

−0.016 (GI haemorrhage)

 EQ-5D-5 L to EQ-5D-3 L US value set - PA

−0.0187

 Wang [35]

− 0.02 (bleeding in general)

 EQ-5D-3 L US tariff - PA

−0.0203

 EQ-5D-5 L UK tariff - PA

−0.0222

 Garg [28]

− 0.025

 EQ-5D-5 L to EQ-5D-3 L UK value set - PA

−0.0258

 EQ-5D-3 L UK tariff - PA

−0.0297

 Kazi [29]

− 0.0308 (extra-cranial)

 Amin [11]

−0.0381 (BARC type 2–4)

 EQ-5D-5 L to EQ-5D-3 L US value set - SA

−0.0405

 EQ-5D-3 L US tariff - SA

−0.0441

 Amin [11]

− 0.0445 (BARC type 3–4)

 EQ-5D-5 L UK tariff - SA

− 0.0465

 Liew [30]

−0.05

 EQ-5D-5 L to EQ-5D-3 L UK value set - SA

−0.0552

 EQ-5D-3 L UK tariff - SA

−0.0621

 Latour-Perez [33]

− 0.13 (serious haemorrhage)

 Jiang [34]

−0.250 (non-fatal bleeding)

 Jiang [36]

−0.250 (non-fatal bleeding)

  1. BARC Bleeding Academic Research Consortium, CABG coronary artery bypass grafting, GI gastrointestinal, PA primary analysis, SA sensitivity analysis